Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, Elzi L, Rauch A, Bernasconi E, Schmid P, Hirschel B.

AIDS. 2011 Jul 31;25(12):1481-7. doi: 10.1097/QAD.0b013e328348dab0.

PMID:
21593661
2.

A randomized crossover study to compare efavirenz and etravirine treatment.

Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, Fayet-Mello A, Elzi L, Genné D, Rauch A, Bernasconi E, Hirschel B; Swiss HIV Cohort Study..

AIDS. 2011 Jan 2;25(1):57-63. doi: 10.1097/QAD.0b013e32833f9f63. Erratum in: AIDS. 2011 Mar 13;25(5):729. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
21076278
3.

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

Waters L, Fisher M, Winston A, Higgs C, Hadley W, Garvey L, Mandalia S, Perry N, Nicola M, Nelson M.

AIDS. 2011 Jan 2;25(1):65-71. doi: 10.1097/QAD.0b013e328341685b.

PMID:
21099666
4.
5.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study..

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
6.

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team..

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.

PMID:
19648823
7.

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R.

AIDS. 2007 Jan 30;21(3):325-33.

PMID:
17255739
8.

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group..

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.

PMID:
19357529
9.

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team..

Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Erratum in: Clin Infect Dis. 2008 Dec 15;47(12):1611.

PMID:
18781872
10.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
11.

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group..

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50.

PMID:
15097150
12.

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).

Gallien S, Journot V, Rozenbaum W, Yéni P, Morlat P, Poizot-Martin I, Reynes J, Reliquet V, Leclercq P, Simon F, Chêne G, Molina JM; ALIZE (ANRS 099) Study Group..

J Antimicrob Chemother. 2011 Jan;66(1):184-91. doi: 10.1093/jac/dkq395.

PMID:
21036772
13.

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.

Int J Infect Dis. 2008 Nov;12(6):e33-8. doi: 10.1016/j.ijid.2007.10.008.

14.
15.

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators..

J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69.

PMID:
23412015
16.

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.

Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, Davis EA, Shaefer M; ESS40013 Study Team..

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):257-64.

PMID:
15980684
17.

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.

HIV Med. 2008 May;9(5):294-9. doi: 10.1111/j.1468-1293.2008.00563.x.

18.

Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.

Briz V, León-Leal JA, Palladino C, Moreno-Perez D, de Ory SJ, De José MI, González-Tomé MI, Martín CG, Pocheville I, Ramos JT, Leal M, Muñoz-Fernández MÁ.

Pediatr Infect Dis J. 2012 Mar;31(3):273-7. doi: 10.1097/INF.0b013e31824580e8.

PMID:
22330165
19.

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV..

AIDS. 2006 Oct 24;20(16):2099-106.

PMID:
17053356

Supplemental Content

Support Center